Newly identified genetic risk variants for celiac disease related to the immune response.
Hunt KA,
Zhernakova A,
Turner G,
Heap GA,
Franke L,
Bruinenberg M,
Romanos J,
Dinesen LC,
Ryan AW,
Panesar D,
Gwilliam R,
Takeuchi F,
McLaren WM,
Holmes GK,
Howdle PD,
Walters JR,
Sanders DS,
Playford RJ,
Trynka G,
Mulder CJ,
Mearin ML,
Verbeek WH,
Trimble V,
Stevens FM,
O'Morain C,
Kennedy NP,
Kelleher D,
Pennington DJ,
Strachan DP,
McArdle WL,
Mein CA,
Wapenaar MC,
Deloukas P,
McGinnis R,
McManus R,
Wijmenga C,
van Heel DA.
Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, 4 Newark Street, London E1 2AT, UK.
Our genome-wide association study of celiac disease previously identified risk variants in the IL2-IL21 region. To identify additional risk variants, we genotyped 1,020 of the most strongly associated non-HLA markers in an additional 1,643 cases and 3,406 controls. Through joint analysis including the genome-wide association study data (767 cases, 1,422 controls), we identified seven previously unknown risk regions (P < 5 x 10(-7)). Six regions harbor genes controlling immune responses, including CCR3, IL12A, IL18RAP, RGS1, SH2B3 (nsSNP rs3184504) and TAGAP. Whole-blood IL18RAP mRNA expression correlated with IL18RAP genotype. Type 1 diabetes and celiac disease share HLA-DQ, IL2-IL21, CCR3 and SH2B3 risk regions. Thus, this extensive genome-wide association follow-up study has identified additional celiac disease risk variants in relevant biological pathways.
PMID: 18311140 [PubMed - indexed for MEDLINE]
PMCID: PMC2673512